Search hospitals > Pennsylvania > Harrisburg

UPMC Pinnacle Harrisburg

Claim this profile
Harrisburg, Pennsylvania 17101
Global Leader in Breast Cancer
Global Leader in Aortic Valve Stenosis
Conducts research for Lung Cancer
Conducts research for Cancer
Conducts research for Atrial Fibrillation
93 reported clinical trials
16 medical researchers
Photo of UPMC Pinnacle Harrisburg in HarrisburgPhoto of UPMC Pinnacle Harrisburg in HarrisburgPhoto of UPMC Pinnacle Harrisburg in Harrisburg

Summary

UPMC Pinnacle Harrisburg is a medical facility located in Harrisburg, Pennsylvania. This center is recognized for care of Breast Cancer, Aortic Valve Stenosis, Lung Cancer, Cancer, Atrial Fibrillation and other specialties. UPMC Pinnacle Harrisburg is involved with conducting 93 clinical trials across 121 conditions. There are 16 research doctors associated with this hospital, such as Liza C. Villaruz, Adam Brufsky, MD, Dan P. Zandberg, and Hemal Gada, MD.

Area of expertise

1Breast Cancer
Global Leader
UPMC Pinnacle Harrisburg has run 15 trials for Breast Cancer. Some of their research focus areas include:
HER2 negative
Stage IV
ER positive
2Aortic Valve Stenosis
Global Leader
UPMC Pinnacle Harrisburg has run 13 trials for Aortic Valve Stenosis.

Top PIs

Clinical Trials running at UPMC Pinnacle Harrisburg

Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Mitral Valve Regurgitation
Aortic Valve Stenosis
Heart Failure
Stroke
ALK Gene Rearrangement
Tricuspid Regurgitation
Cancer
Image of trial facility.

Giredestrant + Hormone Therapy

for Early-Stage Breast Cancer

This trial is testing giredestrant, a medication given after initial treatment to prevent breast cancer from returning. It focuses on patients with a specific type of early-stage breast cancer that is hormone-driven and at higher risk of recurrence. Giredestrant works by blocking the hormone estrogen from helping cancer cells grow. Giredestrant has shown promise in previous studies.
Recruiting2 awards Phase 311 criteria
Image of trial facility.

Chemotherapy Reduction After Surgery

for Breast Cancer

This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Image of trial facility.

Marker-Directed Monitoring

for Breast Cancer

This trial studies if using blood tests to decide when to do scans is as effective as the standard way for monitoring patients with a specific type of breast cancer that has spread. The blood tests act like an early warning system for cancer activity.
Recruiting1 award N/A

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at UPMC Pinnacle Harrisburg?
UPMC Pinnacle Harrisburg is a medical facility located in Harrisburg, Pennsylvania. This center is recognized for care of Breast Cancer, Aortic Valve Stenosis, Lung Cancer, Cancer, Atrial Fibrillation and other specialties. UPMC Pinnacle Harrisburg is involved with conducting 93 clinical trials across 121 conditions. There are 16 research doctors associated with this hospital, such as Liza C. Villaruz, Adam Brufsky, MD, Dan P. Zandberg, and Hemal Gada, MD.